Top Page
Orthocell Ltd
(Sydney:OCC)
Orthocell Ltd (OCC) vs. iShares MSCI Australia ETF (EWA)
Orthocell Ltd Business Overview & Revenue Model
Orthocell Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.32M | 4.24M | 1.53M | 1.02M | 719.52K |
| Gross Profit | 3.69M | 3.06M | 832.52K | 299.88K | -6.40K |
| EBITDA | -11.68M | -9.93M | -11.52M | -11.67M | -9.25M |
| Net Income | -7.18M | -6.25M | -9.11M | -9.04M | -6.15M |
Balance Sheet | |||||
| Total Assets | 26.62M | 29.61M | 37.90M | 19.33M | 23.17M |
| Cash, Cash Equivalents and Short-Term Investments | 20.61M | 24.82M | 11.02M | 16.33M | 20.44M |
| Total Debt | 689.69K | 562.30K | 507.56K | 621.72K | 500.89K |
| Total Liabilities | 22.08M | 23.46M | 27.99M | 2.46M | 2.27M |
| Stockholders Equity | 4.53M | 6.15M | 9.90M | 16.87M | 20.90M |
Cash Flow | |||||
| Free Cash Flow | -7.45M | 13.96M | -6.80M | -4.82M | -5.31M |
| Operating Cash Flow | -6.51M | 14.59M | -6.26M | -4.63M | -5.26M |
| Investing Cash Flow | -942.02K | -631.56K | -535.02K | -188.52K | -55.20K |
| Financing Cash Flow | 3.24M | -164.61K | 1.49M | 709.15K | 14.52M |
Orthocell Ltd Technical Analysis
Orthocell Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | AU$308.45M | ― | -29.77% | ― | 6.07% | 59.09% | |
46 Neutral | C$195.87M | -3.27 | -23.14% | 2.82% | 20.75% | -0.36% | |
| ― | $109.18M | ― | -46.65% | ― | ― | ― | |
| ― | $249.63M | ― | -31.16% | ― | ― | ― | |
47 Neutral | AU$327.08M | ― | -524.68% | ― | 322.26% | -53.98% | |
40 Underperform | AU$99.77M | ― | ― | ― | -33.01% | ||
40 Underperform | AU$124.80M | ― | -85.35% | ― | 315.11% | 51.16% |
Orthocell Ltd Corporate Events
Orthocell Ltd announced the cessation of 250,000 securities due to the expiry of options or other convertible securities that were not exercised or converted by July 13, 2025. This cessation of securities may impact the company’s capital structure but is a routine part of managing financial instruments and does not indicate any immediate operational or strategic shifts.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 1,455,911 fully paid ordinary shares following the exercise of unlisted options, allowing immediate trading under the Corporations Act exemption. This move reflects Orthocell’s strategic efforts to enhance its financial flexibility and support its ongoing product development and market expansion initiatives.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the quotation of 1,455,911 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from July 10, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its growth initiatives in the regenerative medicine sector, potentially impacting its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has achieved its first US sales revenue for its Remplir™ nerve repair product, marking a significant milestone in its commercialization strategy. The company transitioned from receiving US FDA clearance to revenue generation in just over three months, leveraging its network of specialist distributors and logistics partner Uniphar. This development is part of Orthocell’s strategic plan to build familiarity and knowledge among US surgeons, aiming for widespread adoption and revenue growth in the $1.6 billion US nerve repair market.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has bolstered its executive leadership team with the appointments of Jim Piper as Chief Financial Officer and Adam Wood as Chief Commercial Officer. These strategic hires are aimed at supporting the company’s global expansion and commercialization efforts, particularly in the United States, as it seeks to enhance market engagement and product sales. Piper and Wood bring extensive experience in finance and commercial operations, respectively, which is expected to drive Orthocell’s growth and establish Remplir™ as a leading solution in the nerve repair market.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited reported a record revenue of $2.73 million for the June quarter, driven by strong sales of its nerve repair product, Remplir™, in Australia. This marks a 22.8% increase from the previous quarter and the fifth consecutive quarter of record revenue. The company is poised for further growth as it prepares to ramp up Remplir™ sales in the US, supported by a network of 14 specialist nerve distributors across 25 states. With a solid foundation in place, Orthocell aims to capitalize on the US$1.6 billion US nerve repair market, following the successful first surgical use of Remplir™ in the US.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited announced a webinar to discuss the first US surgical use of Remplir™ and the progress of its rollout in the US. This development marks a significant step in Orthocell’s expansion strategy, potentially enhancing its market position in regenerative medicine and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has achieved a significant milestone with the first surgical use of its nerve repair product, Remplir™, in the United States, following FDA clearance. This marks a crucial step in penetrating the US$1.6 billion US nerve repair market, supported by a network of 14 specialist distributors. The successful surgery in Ohio highlights Orthocell’s commitment to expanding its market presence and driving sales growth, with expectations of increased revenue in the second half of 2025.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has announced compelling interim results from a study demonstrating the superiority of its Remplir product over traditional suture-only nerve repair techniques. The study, which supports the company’s US sales rollout, shows that Remplir leads to better nerve regeneration and earlier muscle function recovery, reducing adverse tissue reactions associated with sutures. These findings are expected to drive rapid market adoption and redefine the nerve repair market, with Orthocell targeting a total addressable market of over $3.5 billion across selected jurisdictions.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 1,367,852 new shares following the exercise of unlisted options, allowing immediate trading under the Corporations Act exemption. This move is part of Orthocell’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its stakeholders by increasing liquidity and financial flexibility.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the quotation of 1,367,852 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 10, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for further development and expansion of its regenerative medicine products.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.28 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has received regulatory approval to commence sales of its flagship nerve repair product, Remplir™, in Hong Kong, a strategically important market in the Asia Pacific region. This approval, granted ahead of schedule, adds to Orthocell’s growing portfolio of approvals in the US, Canada, Australia, New Zealand, Singapore, and Thailand, with further applications planned for the EU and UK. The company is leveraging external distributors to penetrate new markets while focusing internal resources on the US market. With a strong cash position and no debt, Orthocell is well-positioned to expand its commercial footprint and increase revenues.
Orthocell Ltd has rapidly expanded its US distribution network for its nerve repair product, Remplir™, appointing 12 distributors across 21 states, surpassing its initial target. This strategic expansion, following FDA clearance, is expected to significantly boost the company’s revenue and market penetration in the US$1.6 billion nerve repair market, leveraging experienced distributors and internal sales teams to drive growth.
Orthocell Limited has received regulatory approval from Health Canada to sell its nerve repair product, Remplir™, in the Canadian market, which is valued at US$75 million. This approval expands the total addressable market for Remplir to US$1.8 billion, following recent approvals in the US and Thailand, and existing approvals in Australia, New Zealand, and Singapore. The company plans to appoint local distributors in Canada to drive sales, with first sales expected in the second half of 2025. Orthocell is well-funded with A$31.7 million in cash reserves, positioning it to capitalize on these new market opportunities and continue its global expansion strategy.
Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development that could impact the company’s market positioning and stakeholder interests, as regulatory approvals are crucial for product commercialization and market expansion.
Orthocell Limited has requested a trading halt on its securities pending an announcement about a new regulatory approval for its product, Remplir. This move indicates a significant development for the company, potentially impacting its market position and stakeholder interests as it awaits the formal announcement.
Orthocell Ltd has received regulatory approval from the Thai FDA to commence sales of its nerve repair product Remplir™ in Thailand, a market valued at US$84 million. This approval, achieved through an expedited registration pathway, significantly enhances Orthocell’s presence in the Asia Pacific region and is expected to drive revenue growth. The company plans to partner with a local distributor and anticipates first sales in the second half of 2025. With a strong cash reserve and no debt, Orthocell is well-positioned to expand its global footprint and capitalize on the growing demand for nerve repair solutions.
Orthocell Limited has appointed its first four US distributors for its nerve repair product, Remplir™, following its recent FDA 510(k) clearance. This strategic move allows Orthocell to enter the US$1.6 billion US nerve repair market, with initial sales expected soon. The company plans to expand its distributor network to approximately 10 by mid-2025, covering around 25 states, to accelerate market penetration and revenue growth. Orthocell’s strong financial position and existing inventory support its US rollout, positioning it well for success in the competitive nerve repair industry.